Literature DB >> 1329319

Evolutionary relationships among the gnat-transmitted orbiviruses that cause African horse sickness, bluetongue, and epizootic hemorrhagic disease as evidenced by their capsid protein sequences.

H Iwata1, M Yamagawa, P Roy.   

Abstract

The amino acid sequences of four major capsid proteins of African horse sickness virus (serotype 4, AHSV-4) have been compared with those of Bluetongue virus of sheep. Epizootic hemorrhagic disease virus of deer, and the phylogenetic relationships established. Complete nucleotide sequence analysis of three RNA segments (L2, L3, and M6) of AHSV-4 and their encoded products, VP2, VP3, and VP5, together with previously published data for VP7 (Roy et al., 1991), have revealed that of the four capsid proteins the innermost protein, VP3, is the most conserved, and the outermost protein, VP2, is the most variable. Some 57-58% of the aligned BTV-10 and EHDV-1 VP3 amino acids are identical with those of AHSV-4. This compares to an identity of 79% between the BTV and EHDV VP3 sequences. For the VP7 proteins 64% of the aligned amino acids are identical between BTV-10 and EHDV-1, while they share 44-46% amino acid residues with the aligned VP7 protein of AHSV-4. By contrast, the VP2 proteins of the three viruses share only 19-24% identical amino acids. Various other comparative analyses of the proteins indicate that the VP2 species of the three orbiviruses are similar. Unlike VP2, the other outer capsid protein, VP5 is more conserved among the three viruses. On alignment, the VP5 of AHSV-4 has some 43-45% identical amino acids with that of BTV-10 and EHDV-1. Between BTV and EHDV, 62% of the aligned sequences are identical.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1329319     DOI: 10.1016/0042-6822(92)90187-t

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  8 in total

1.  RGD tripeptide of bluetongue virus VP7 protein is responsible for core attachment to Culicoides cells.

Authors:  B H Tan; E Nason; N Staeuber; W Jiang; K Monastryrskaya; P Roy
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Identification of domains in bluetongue virus VP3 molecules essential for the assembly of virus cores.

Authors:  S Tanaka; P Roy
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

3.  Rapid detection of African horsesickness virus by the reverse transcriptase polymerase chain reaction (RT-PCR) using the amplimer for segment 3 (VP3 gene).

Authors:  K Sakamoto; R Punyahotra; N Mizukoshi; S Ueda; H Imagawa; T Sugiura; M Kamada; A Fukusho
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

4.  Serotype specific primers and gel-based RT-PCR assays for 'typing' African horse sickness virus: identification of strains from Africa.

Authors:  Narender S Maan; Sushila Maan; Kyriaki Nomikou; Manjunatha N Belaganahalli; Katarzyna Bachanek-Bankowska; Peter P C Mertens
Journal:  PLoS One       Date:  2011-10-20       Impact factor: 3.240

5.  Assembly of Replication-Incompetent African Horse Sickness Virus Particles: Rational Design of Vaccines for All Serotypes.

Authors:  Valeria Lulla; Aleksei Lulla; Kerstin Wernike; Andrea Aebischer; Martin Beer; Polly Roy
Journal:  J Virol       Date:  2016-07-27       Impact factor: 5.103

6.  Analysis of Conserved, Computationally Predicted Epitope Regions for VP5 and VP7 Across three Orbiviruses.

Authors:  Bonnie L Russell; Nishal Parbhoo; Samantha Gildenhuys
Journal:  Bioinform Biol Insights       Date:  2018-01-31

Review 7.  African Horse Sickness: A Review of Current Understanding and Vaccine Development.

Authors:  Susan J Dennis; Ann E Meyers; Inga I Hitzeroth; Edward P Rybicki
Journal:  Viruses       Date:  2019-09-11       Impact factor: 5.048

8.  Heterogeneity of the L2 gene of field isolates of bluetongue virus serotype 17 from the San Joaquin Valley of California.

Authors:  C A de Mattos; C C de Mattos; B I Osburn; N J MacLachlan
Journal:  Virus Res       Date:  1994-01       Impact factor: 3.303

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.